LZAGF.US Lonza Group Ltd

Healthcare Biotechnology USA Stocks
796.71 USD
Close of Nov 16, 2026
557.54 841.45
Market cap
USD 55.6B
P/E
40.3x
P/B
5.65x
ROE
28.9%
Dividend yield
0.81%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is LZAGF.US undervalued?

Graham number

The Graham number of Lonza Group Ltd cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Lonza Group Ltd fundamental analysis

No fundamental analysis for Lonza Group Ltd yet.

Lonza Group Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Lonza Group Ltd

Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manuf…

Full company profile